Halozyme Therapeutics (HALO) Change in Acquisitions & Divestments (2013 - 2026)

Halozyme Therapeutics (HALO) has 14 years of Change in Acquisitions & Divestments data on file, last reported at $9.0 million in Q1 2026.

• Change in Acquisitions & Divestments for Q1 2026 came in at $9.0 million, down 82.06% year-over-year; the trailing twelve-month figure through Mar 2026 was $681.1 million (up 108.85% YoY), and the FY2025 annual result was $722.2 million, up 82.58% from the prior year.
• Change in Acquisitions & Divestments fell to $9.0 million in Q1 2026 per HALO's latest filing, from $273.4 million in the prior quarter.
• Over five years, Change in Acquisitions & Divestments peaked at $590.0 million in Q2 2022 and troughed at $9.0 million in Q1 2026.
• A 5-year average of $130.3 million and a median of $82.6 million in 2023 frame the typical range for Change in Acquisitions & Divestments.
• The sharpest annual moves came in 2022 and 2023: Change in Acquisitions & Divestments surged 667.59% in 2022, then sank 90.95% in 2023.
• A 5-year view of Change in Acquisitions & Divestments shows it stood at $20.1 million in 2022, then declined by 22.52% to $15.6 million in 2023, then surged by 438.34% to $84.0 million in 2024, then surged by 225.54% to $273.4 million in 2025, then slumped by 96.71% to $9.0 million in 2026.
• Business Quant data shows HALO's Change in Acquisitions & Divestments at $9.0 million in Q1 2026, $273.4 million in Q4 2025, and $209.6 million in Q3 2025.